NFE2L2 and prostate carcinoma: SFN treatment has been shown to demethylate the nuclear factor-erythroid factor 2-related factor-2 (Nrf2) gene promoter, leading to increased expression in prostate cancer cells [125], which is reflected in decreased tumor cell proliferation [126].